Genmab — April 2023

[gentogen]

免疫功坊股份有限公司Immunwork

Immunwork, Inc. located in Taipei, Taiwan was founded in October 2014.After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island. Immunwork focuses on the research and development of a class of new drugs, which are created based on our proprietary “T-E pharmaceuticals” technology platform. The first group of new drugs is for treating several types of cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots.

免疫功坊股份有限公司 IMMUNWORK (www.immunwork.com)

[Sukkeralf]

Lidt om ADC generelt

[Sukkeralf]

The Clinical Landscape Of ADCs In 2023: Diverse Technologies, Narrow Target

Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the potency of...

(www.clinicalleader.com)

[peter12]

De behøver så ikke at buge dara i den ADC

[Solsen]

Det er jo netop giftstoffet der ofte er problemet mht sideeffects. Men spændende at følge udviklingen og lad os håbe, at Genmab er med i front. Fantastisk for patienter hvis nævnte effekt kan opnås uden væsentlig forringelse af bivirkningerne.

[Bulder]

Fandt dette: “ Lysis af celler foregår hos højere organismer som fx mennesket under indvirkning af komplementsystemet: I celler, der bliver angrebet af en virus eller en bakterie, dannes der via dette system porer i cellemembranen, der tillader vand at trænge ind i cellen, som herved sprænges.” https://denstoredanske.lex.dk/lysis

[Bulder]

I abstr som vi diskuterede før forårsager TE-1146 netop lysis. Det kunne pege på hex-38, som netop har aktivering af komplementsystemet, som sin stærke side.

[Bulder]

Abstr er i øvrigt late breaking på AACR, så nogen opsigt må det have vakt.

[StockBull]

USD på vej mod 6.5 https://www.linkedin.com/pulse/teknik-hjælper-jens-schjerning/?midToken=AQH9tRHGf_Xm-Q&midSig=2yXqGbG6E2GqI1&trk=eml-email_series_follow_newsletter_01-newsletter_hero_banner-0-open_on_linkedin_cta&trkEmail=eml-email_series_follow_newsletter_01-newsletter_hero_banner-0-open_on_linkedin_cta-null-13d6e0~lgj22fs9~7t-null-null&eid=13d6e0-lgj22fs9-7t

[StockBull]

TA ugekort ved at gå i køb som kunne indikere en længere optur på 3-5 mdr a la 2021 og 2022. Sender et kort når købssignalet kommer i løbet af April. Dag kortet gav jo købssignal 14 Marts så indtil vidre fin optur.

[JKY_VH]

Tak SB

[ProinvestorNEWS]

Merck & Co. agrees to buy Prometheus for $10.8 billion https://firstwordpharma.com/story/5728300

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen.

[bibob]

God morgen.

[ProinvestorNEWS]

MorphoSys : Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi https://www.proinvestor.com/investornyt/968633/morphosys-long-term-data-show-prolonged-durable-responses-in-dlbcl-patients-treated-with-monjuvi

[Pensionisten]

Så rr det jo i morgen middag, vi får nye tal fra J&J.

[Darvin]

Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

[Darvin]

Genmab is entering the therapeutic area of immunology and inflammation - ventet

[Budweis]

Collaboration Details
As per the agreement, argenx and Genmab will each have access to the suites of proprietary antibody technologies of both companies to advance the identification of lead antibody candidates against differentiated disease targets. Under the terms of the agreement, argenx and Genmab will jointly discover, develop and commercialize products emerging from the collaboration while equally sharing costs as well as any potential future profits. The collaboration will initially focus